超《TRIPS协定》条款对药品专利强制许可的变异及应对策略  

Strategies to Deal with the Disorder Brought by the TRIPS-plus Agreement Clause on the Drug Patent Compulsory License System

作　　者：陈庆[1,2] 

机构地区：[1]中南财经政法大学知识产权研究中心 [2]南京师范大学泰州学院

出　　处：《知识产权》2013年第6期80-85,共6页Intellectual Property

基　　金：教育部人文社会科学重点研究基地重大项目(编号:11JJD820006)基金资助

摘　　要：签署双边自由贸易协定是后《TRIPS协定》时代美国、欧盟等发达国家提高知识产权保护标准的又一举措,由此所产生的超《TRIPS协定》条款使得药品专利强制许可制度被变异,难以实施。当药品试验数据专有权或药品专利链接制度对药品专利强制许可造成障碍时,立法上应明确其冲突解决方式,有利于避免今后我国的药品专利强制许可受到不利影响。Signing bilateral free trade agreements is another step adopted by the developed countries, including the United States and the European Uion, to improve the protection standard of intellectual property rights in the post-TRIPS age. It generates TRIPS-plus clauses which cause difficulties in implementation of drug patent compulsory license system. When pharmaceutical test data exclusivity rights or the system of drug patent links cause disorder to compulsory licensing of medicine, legislative measures should be adopted to resovle those conficts, in case China might be adversely affected in the future.

关 键 词：超《TRIPS协定》条款 药品专利强制许可 策略 

分 类 号：D997.1[政治法律—国际法学]